·                                
 
The idea that Botox (botulinum toxin A) could help with 
depression is
being explored by, Allergan, despite the latest 
trial showing patchy results.
Based on the “facial feedback” hypothesis, which holds that 
facial
movement can influence emotional experience, 
Allegan is hopeful the drug’s
anti-wrinkle and anti-frowning 
formula can  be used to improve mood.
Anecdotal evidence suggests Botox is already used off-label 
for this
purpose.
Yet results from a phase II study of almost 260 patients show 
that Botox is unable to meaningfully reduce depression after 
six weeks compared
with placebo.
A 30-unit dose of Botox appears to be better at reducing 
depression than
placebo, but the results are clinically 
insignificant.
The study also suggests that less is more, with a stronger 50-
unit dose
of the drug showing no benefit compared with the 
placebo.
Nonetheless, Allergan says it will press ahead with phase III.
“We are encouraged by these data and the potential impact 
on adults with
major deperssive disorder,” says David 
Nicholson, Allergan’s chief research and
development officer.
“Given our in-depth and extensive clinical trial experience in 
the
central nervous system, including depression, we plan to 
move forward and
develop a phase III program for a 
potential new treatment option for patients.”


Commenti
Posta un commento